FDA Approves Edoxaban to Reduce Stroke in AFib, VTE

January 9, 2015 9:11 PM

5 0

FDA Approves Edoxaban to Reduce Stroke in AFib, VTE

The U.S. FDA has approved edoxaban (Savaysa, Daiichi Sankyo) to reduce the risk of stroke and systemic embolism (SE) in patients with non-valvular atrial fibrillation as well as for the treatment of venous thromboembolism.

The once-daily Xa-inhibitor tablet produced by Daiichi Sankyo Company, Limited was found to be non-inferior to warfarin in the ENGAGE AF-TIMI 48 trial in the reduction of stroke risk. The rate of cardiovascular death in Savaysa was also found to be less than warfarin (2.95% per year vs. 3.59% per ye...

Read more

To category page

Loading...